Paper
Design and synthesis of a novel series of 4-heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR.
Published Mar 1, 2017 · Christiana I. Iwuagwu, D. King, I. Mcdonald
Bioorganic & medicinal chemistry letters
Q2 SJR score
9
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
This study developed a novel series of 7 nicotinic receptor agonists, which show potential in improving cognition in the mouse novel object recognition model.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.
BMS-933043, a selective 7 nACh receptor partial agonist, shows potential in treating cognitive dysfunction in schizophrenia by targeting specific neuronal nicotinic acetylcholine receptors.
2017·11citations·D. King et al.·ACS medicinal chemistry letters
ACS medicinal chemistry letters
Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship.
The new series of spiroimidates shows excellent selectivity for 7 nicotinic receptors, with potential for improving cognition in preclinical rodent models.
2016·15citations·J. Cook et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.
TC-5619 showed no statistical benefit for negative or cognitive symptoms in schizophrenia patients.
2016·85citations·D. Walling et al.·Schizophrenia bulletin
Schizophrenia bulletin
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia
Encenicline, a selective 7 nicotinic acetylcholine receptor agonist, showed clinically meaningful improvements in cognition and function in patients with schizophrenia.
2015·119citations·R. Keefe et al.·Neuropsychopharmacology
Neuropsychopharmacology
Political Donations and Democratic Equality in Canada
Wealthier Canadians are more likely to contribute to political parties, with a low donation cap and disproportionate weight in total donation dollars.
2014·6citations·Bri Carmichael et al.·Canadian Parliamentary Review
Canadian Parliamentary Review
Citations
Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors
The 7-type nicotinic acetylcholine receptor (nAChR) is a potential therapeutic target for various diseases, with potential importance for both ionotropic and metabotropic signaling.
2021·42citations·R. Papke et al.·Pharmacological Reviews
Pharmacological Reviews
Design, synthesis and biological activities of piperidine-spirooxadiazole derivatives as α7 nicotinic receptor antagonists.
Piperidine-spirooxadiazole derivatives show potential as selective 7 nicotinic receptor antagonists, offering potential for therapeutic targeting of inflammation-related diseases.
2020·11citations·Han Zhang et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Selective α7 nicotinic receptor agonists and positive allosteric modulators for the treatment of schizophrenia – a review
Selective 7 nicotinic receptor agonists and positive allosteric modulators may offer a promising treatment for schizophrenia by minimizing receptor desensitization and enhancing efficacy.
2020·15citations·Kirsten Antonio-Tolentino et al.·Expert Opinion on Investigational Drugs
Expert Opinion on Investigational Drugs
Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders.
5-HT3 receptor antagonists show potential in treating neuropsychiatric disorders like schizophrenia, depression, anxiety, and drug abuse, with novel structures, functions, and pharmacology being developed over the past 10 years.
2020·38citations·Radomír Jůza et al.·Medicinal research reviews
Medicinal research reviews
Discovery of fused heterocyclic carboxamide derivatives as novel α7-nAChR agonists: Synthesis, preliminary SAR and biological evaluation.
Fused heterocyclic carboxamide derivatives show potential as novel 7-nAChR agonists, with aromaticity playing a key role in their activity and selectivity over other related subtypes.
2019·7citations·Yu Xue et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Design and synthesis of a novel series of (1'S,2R,4'S)-3H-4'-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2'-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor.
This study successfully synthesized a series of compounds with high affinity for the 7 nicotinic receptor and good selectivity against the related 5-HT 3A receptor.
2017·3citations·J. Cook et al.·Bioorganic & medicinal chemistry letters
Bioorganic & medicinal chemistry letters
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.
BMS-933043, a selective 7 nACh receptor partial agonist, shows potential in treating cognitive dysfunction in schizophrenia by targeting specific neuronal nicotinic acetylcholine receptors.
2017·11citations·D. King et al.·ACS medicinal chemistry letters
ACS medicinal chemistry letters